The aim of this work was to study the effect of supplementation of iron and vitamin C therapy to hemodialysis patients, hoping that this therapy is effective in the treatment of anaemia in these patients. In this work, 40 stable hemodialysis patients suffering from severe to moderate anemia not receiving any form of replacement therapy (i.e., neither erythropoietin (EPO) nor iron), were selected and divided into two groups: The first group was treated by injection with ferrosac 100 mg/5ml twice a week for 3 months, and the second group was treated by injection with 500 mg/2.5ml of vitamin C in combination with 100 mg/5ml ferosac twice a week for three months. The results of this study indicated that: There was a significant decrease in both urea and creatinine in hemodialysis patients after i.v. treatment of ferosac alone (100 mg/5ml) "group I" and combined ferosac (100 mg/5ml) with ascorbic acid (500 mg/2.5ml) "group II" twice weekly for 3 months. There was a significant increase in hemoglobin concentration and serum iron in both hemodialysis patient groups (I&II) after treatment, the highly increase markedly occurred in group II rather than group I after treatment. Moreover, there was a significant decrease in serum ferritin concentration in group I and a more pronounced decrease in group II after treatment, indicating the importance of vitamin C in decreasing the serum ferritin level and therefore the better correction of anemia.
INTRODUCTION
The kidney is responsible for maintaining both volume and ionic composition of the body fluids excreting fixed or non-volatile metabolic waste products such as creatinine, urea, uric acid and eliminating exogenous drugs and toxins. It also catabolizes small molecular weight proteins and is responsible for most metabolic functions (1) . The kidney is a major endocrine organ, since it produces renin, erythropoietin, 1,25 dihydroxy cholecalciferol, prostaglandins, and kinins. It also serves as a target organs for many hormones (2) . Renal failure is a clinico-biochemical syndrome resulting from failure of the kidney function.
Renal failure may be acute but more commonly it is chronic. The goal of therapy for iron deficiency anemia is to supply sufficient iron to correct the anemia and replenish storage iron. The fact that 150 mg of iron are required to synthesize 1 g of hemoglobin can be used to approximate the amount of parenteral iron necessary for heme synthesis during the correction phase (7) .
It is now well established that intravenous (i.v.) iron supplementation is essential in the majority of patients to maintain an optimal iron supply to the bone marrow for red blood cell production. (8,9) Vitamin C may be involved in tyrosin metabolism, microsomal drug metabolism, synthesis of epinephrine and antiinflammatory steroid by the adrenals, folic acid metabolism, and leukocyte functions (10, 11) .
Absorption of Fe 2+ is enhanced by simultaneous ingestion of vitamin C. Ascorbic acid, a reducing agent, is able to release iron from ferritin and mobilize iron from the reticuloendothelial system to transferrin. This leads to an increased iron availability. (12) Vitamin C is an antioxidant. It protects against the harmful effects of pollution, prevents cancer, protects against infection, and enhances immunity (13) .
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The aim of this work is to study the effect of combined supplementation of iron and vitamin C therapy to hemodialysis patients, hoping that this therapy is effective in the treatment of anaemia in these patients.
MATERIAL and METHODS
This study was performed on forty endstage renal disease patients (28 males and 12 females) undergoing maintenance hemodialysis. Mean age was 50 years (range 22-70 years). All the patients studied had been on hemodialysis for at least one year before being included in the study.
All patients were dialyzed in Nephrology
Unit, Medical Research Institute (Alexandria University, Egypt). All patients were anemic, blood hemoglobin averaged 7.64 g/dl and serum ferritin was less than 300 ng/dl. They were divided randomly into two groups:
Comprising 20 hemodialysis patients were intravenously infused ferrosac,
i.e., ferric-hydroxide saccharate complex, manufactured by SPIMACO, Saudia Arabia, 100 mg/5ml ferrosac twice a week for three months.
Group II:
Comprising 20 hemodialysis patients were supplemented intravenous, 100 mg ferrosac combined with 500 mg/2.5ml vitamin C twice a week for three months.
Preparation of the samples: Blood samples
were collected before dialysis session by routine venupuncture using silicon red evacuated blood tubes without anticoagulant and EDTA tubes. Separation of serum was obtained by centrifugation at 500 g for 10 min.
Serum was divided into aliquots and frozen and stored at -20oC until analyzed.
The prepared samples were used to determine the following parameters:
1-Serum urea using the method of Orsonneau et al., (14) 2-Serum creatinne.
using the method of Rosano et al., (15) 3-Serum albumin using the method of Doumas, (16) 4-Blood haemoglobin using the method of Dacie and Lewis ., (17) 5-Serum iron using the method of Burtis and Ashwood (18), and 6-Serum ferretin using the method of Zanella et al. (19) Measurements were carried out on Labo Med, Inc. USA spectrophotometer. The present study was done to evaluate the effect of administration of iron alone (ferrosac, 100 mg/5ml twice a week for 3 months), as well as, combined iron and ascorbic acid (100 mg/5ml ferrosac + 500 mg/2.5 ml vitamin C twice a week for 3 months) on serum urea, creatinine, albumin, blood hemoglobin, serum iron and ferritin. The study reveals significant differences in serum urea and creatinine levels in hemodialysis patients after i.v. treated with ferrosac alone and more pronounced significance if combined with ascorbic acid. Intravenous ascorbic acid can effectively improve the functional iron deficient erythropoiesis associated with iron overload in hemodialysis patients (11) .
Results
This study indicated a significant increase in hemoglobin concentration and serum iron in hemodialysis patients after i.v. treatment with ferrosac (100 mg/5ml) twice weekly for 3 months. 
